On August 14, 2023 Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, reported that the company will end their collaboration with Akoya Biosciences to co-develop an automated RNAscope workflow for use with the PhenoCycler-Fusion System (Press release, Bio-Techne, AUG 14, 2023, View Source [SID1234634372]). The decision was made following best efforts to achieve the intended program goals.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Bio-Techne remains focused on providing the greatest value to the spatial biology community," said Kim Kelderman, President of Bio-Techne’s Diagnostics and Genomics Segment. "We are actively expanding the capabilities of our gold-standard RNAscope technology to enable greater utility in multiomic spatial applications and plan to accelerate the development and commercialization of the first fully automated and scalable spatial multiomics workflow on the Lunaphore COMET system."

Bio-Techne will continue to support its customers utilizing RNAscope assays in conjunction with Opal reagents and PhenoImager HT systems purchased from Akoya.